OAKVILLE, ON, Dec. 15, 2017 /CNW/ - Concordia International
Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on
becoming a leader in European specialty, off-patent medicines, today announced that at the request of the Investment Industry
Regulatory Organization of Canada ("IIROC"), the Company is confirming that it is unaware at
this time of any material change in its operations that would account for the recent increase in market activity.
Capital Structure Realignment Update
As previously announced, the Company commenced proceedings under the Canada Business Corporations Act (the "CBCA") in
an effort to realign its capital structure. The Company continues to advance ongoing discussions with its debtholders in this
effort, and is focused on realigning its capital structure on a consensual basis.
In connection with the Company's efforts to advance a potential recapitalization transaction, the Company has determined to
defer the payment of the approximately $37.5 million of interest due today on its 9.5% senior
unsecured notes. Such deferral of the interest payment does not result in an Event of Default until the expiry of the
30-day grace period, and any default or Event of Default in respect of the non-payment of the foregoing interest amount is
subject to the stay of proceedings granted in the Company's CBCA proceedings. It is expected that the foregoing interest
payment will be addressed as part of any recapitalization transaction that may be completed by the Company.
About Concordia
Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and
off-patent products, and sales in more than 90 countries. Going forward, the Company is focused on becoming a leader in European
specialty, off-patent medicines.
Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries,
operates out of facilities in Bridgetown, Barbados; London,
England and Mumbai, India.
Notice regarding forward-looking statements and information
This press release includes forward-looking statements within the meaning of the United States Private Securities Litigation
Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws, regarding Concordia and its
business, which may include, but are not limited to statements relating to Concordia's focus on realigning its capital structure
on a consensual basis, discussions with Concordia's lenders and their advisors with respect the proposed recapitalization
transaction, a proposed recapitalization transaction, the completion of a proposed recapitalization transaction including
obtaining any necessary approvals and the expected timing thereof, protection for the Company and its subsidiaries against
defaults and any related steps or actions under CBCA proceedings, the deferred interest payment being addressed as part of any
recapitalization transaction that may be completed by Concordia and Concordia becoming a leader in European specialty, off-patent
medicines. Often, but not always, forward-looking statements and forward-looking information can be identified by the use of
words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or
variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current
expectations of Concordia's management, and are based on assumptions and subject to risks and uncertainties. Although Concordia's
management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks
associated with Concordia's securities, the inability to negotiate with Concordia's lenders, risks associated with a proposed
recapitalization transaction including the inability to complete a proposed recapitalization transaction or complete a proposed
recapitalization transaction in a timely or efficient manner, the inability to reach a consensual transaction with holders of the
Company's debt, the CBCA process not providing the protection sought by Concordia, third parties not complying with the CBCA
order and taking steps against Concordia and its subsidiaries, the inability to address deferred payments as part of any
recapitalization transaction, risks associated with developing new product indications, increased indebtedness and leverage, the
inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, the inability to repay debt
and/or satisfy future obligations, risks associated with Concordia's outstanding debt, risks associated with the geographic
markets in which Concordia operates and/or distributes its products, risks associated with fluctuations in exchange rates
(including, without limitation, fluctuations in currencies), risks associated with the use of Concordia's products to treat
certain diseases, the pharmaceutical industry and the regulation thereof, regulatory investigations, the failure to comply with
applicable laws, risks relating to distribution arrangements, possible failure to realize the anticipated benefits of
acquisitions and/or product launches, risks associated with the integration of assets and businesses into Concordia's business,
product launches, the inability to launch products, the fact that historical and projected financial information may not be
representative of Concordia's future results, the failure to obtain regulatory approvals, economic factors, market conditions,
acquisition opportunities, risks associated with the acquisition and/or launch of pharmaceutical products, risks regarding
clinical trials and/or patient enrolment into clinical trials, the equity and debt markets generally, risks associated with
growth and competition (including, without limitation, with respect to Concordia's niche, hard-to-make products), general
economic and stock market conditions, risks associated with the United Kingdom's exit from the
European Union (including, without limitation, risks associated with regulatory changes in the pharmaceutical industry, changes
in cross-border tariff and cost structures and the loss of access to the European Union global trade markets), risks related to
patent infringement actions, the loss of intellectual property rights, risks and uncertainties detailed from time to time in
Concordia's filings with the Securities and Exchange Commission and the Canadian Securities Administrators and many other factors
beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual
actions, events or results to differ materially from those described in forward-looking statements and forward-looking
information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or
intended. No forward-looking statement or forward-looking information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and forward-looking information speak only as of the date on which they are made and
Concordia undertakes no obligation to publicly update or revise any forward-looking statement or forward-looking information,
whether as a result of new information, future events, or otherwise.
SOURCE Concordia International Corp.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/December2017/15/c7391.html